An essential mode of acquired resistance to radiotherapy (RT) appears to be promotion of tumor cell motility and invasiveness in various cancer types, including glioblastoma, a process resembling 'evasive resistance'. Hence, a logical advancement of RT would be to identify suitable complementary treatment strategies, ideally targeting cell motility. Here we report that the combination of focal RT and mammalian target of rapamycin (mTOR) inhibition using clinically relevant concentrations of temsirolimus (CCI-779) prolongs survival in a syngeneic mouse glioma model through additive cytostatic effects. In vitro, the mTOR inhibitor CCI-779 exerted marked anti-invasive effects, irrespective of the phosphatase and tensin homolog deleted on chromosome 10 status and counteracted the proinvasive effect of sublethal irradiation. Mechanistically, we identified regulator of G-protein signaling 4 (RGS4) as a novel target of mTOR inhibition and a key driver of glioblastoma invasiveness, sensitive to the anti-invasive properties of CCI-779. Notably, suppression of RGS4-dependent glioma cell invasion was signaled through both mTOR complexes, mTORC1 and mTORC2, in a concentration-dependent manner, indicating that high doses of CCI-779 may overcome tumor-cell resistance associated with the sole inhibition of mTORC1. We conclude that combined RT and mTOR inhibition is a promising therapeutic option that warrants further clinical investigation in upfront glioblastoma therapy.
INTRODUCTION
Partial brain radiotherapy (RT) is the most effective, single treatment modality against malignant glioma. Despite its efficacy, an undesirable proinvasive stimulus of therapeutic radiation has been delineated, 1,2 which may explain distant recurrences. 3 It has been proposed that RT can eventually act as a force driving enhanced tumor cell invasion into surrounding healthy tissue, a process that resembles the concept of 'evasive resistance'. 4 To overcome this often insidious consequence and to optimize RT, it is a major goal to integrate RT and anti-invasive strategies into one combined treatment concept. Ongoing phase II/III trials in glioblastoma therefore combine inhibitors of a n b 3 -and a 5 b 1 -integrins or protein kinase Cb with RT.
Serving as a central signaling hub integrating multiple intraand extracellular cues, the serine/threonine kinase mammalian target of rapamycin (mTOR) is an attractive anticancer target. mTOR is involved in the formation of at least two multi-protein complexes, mTORC1 and mTORC2, that direct cell metabolism, growth, proliferation, survival and angiogenesis. The rapamycinsensitive mTORC1 essentially mediates phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT/PKB) signals. Furthermore, through its direct phosphorylation of the ribosomal protein S6 (RPS6) kinase 1 and the eukaryotic translation initiation factor 4E binding protein 1, the mTORC1 promotes anabolic processes, including biosynthesis of proteins, lipids and organelles, and limits catabolic processes such as autophagy. 5 Signaling through mTORC2 is less well understood, but S 473 phosphorylation of AKT by mTORC2 implicates mTOR in acting both upstream and downstream of AKT.
6 mTORC2 is involved in cytoskeletal organization 7 and might thus regulate cancer cell motility, migration and invasion.
Activation of the signaling network engaged by the PI3K/AKT/ mTOR axis frequently occurs by activation of receptor tyrosine kinases, for example, via amplification or mutational activation of the epidermal growth factor receptor (EGFR) (45%), or by mutations or deletions in the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) tumor suppressor gene (30-40%) , and thus concerns the majority of primary glioblastomas. 8 Preclinical studies have suggested an enhanced antitumoral activity of mTOR inhibition in PTEN-deficient tumor models, 9, 10 and activation of the PI3K/AKT/mTOR pathway has been associated with reduced survival of glioma patients. 11 Consequently, this signaling pathway has been subjected to a number of single-or multi-targeted therapies, including the mTOR inhibitor rapamycin or its derivatives, the 'rapalogs' everolimus (RAD001), deforolimus (AP23573) and temsirolimus (CCI-779). 12 However, in relapsed glioblastoma, targeting the EGFR/PI3K/AKT/ mTOR signaling pathway failed to demonstrate convincing clinical activity, neither for mTOR inhibition alone, nor in combination with EGFR inhibition. [13] [14] [15] The experience with the alkylating agent temozolomide teaches that agents with limited activity at recurrence may still significantly modify the course of disease in glioblastoma when combined with RT upfront. 16 Accordingly, mTOR inhibition may still be an option for newly diagnosed, that is, treatment-naive glioblastomas that likely lack some of the mechanisms of resistance met at recurrence. CCI-779 (Torisel) has been approved for advanced renal cell carcinoma 17 and relapsed or refractory mantle cell lymphoma. 18 Cytostatic effects of CCI-779 on tumor cells could complement the genotoxic activity of radiation therapy in upfront treatment of glioblastoma. 19, 20 Additionally, mTOR inhibition could counteract induction of a proinvasive phenotype by RT, a controversial adverse effect of RT that has been suggested to promote tumor progression or recurrence in experimental studies. 2 Therefore, the rationale of the present study was to test the biological effects of mTOR inhibition when combined with ionizing radiation through concomitant suppression of cell invasion, and to unravel underlying molecular mechanisms.
RESULTS
The combination of RT and CCI-779 suppresses glioma growth and prolongs survival in a syngeneic mouse glioma model in vivo To investigate whether clinically relevant doses of the mTOR inhibitor, CCI-779, have activity in an immunocompetent mouse model, we tested CCI-779 at 20 mg/kg alone or in combination with single-dose cranial RT at 6 Gy. Clinically relevant doses of CCI-779 range from 25 to 75 mg per week flat dosing, which corresponds, in an averagely proportioned male (180 cm, 75 kg), to 4.2-33 mg/kg mouse weight (http://www.accessdata.fda.gov/ scripts/cder/onctools/animalquery.cfm). For this purpose, we used the highly tumorigenic PTEN wild-type spontaneous murine astrocytoma (SMA) cell line SMA-560 derived from inbred VM/Dk mice. 21 We confirmed its responsiveness to CCI-779 by demonstrating reduced phosphorylation of murine RPS6, a direct substrate of mTORC1-phosphorylated S6 kinase 1 that correlates with the mTORC1 activity 22 ( Figure 1a) . Following orthotopic implantation of these cells into VM/Dk mice, we evaluated glioma growth by cranial magnetic resonance imaging (MRI; Figure 1b Irradiation-combined mTOR inhibition induces cytostatic anti-glioma effects We then investigated chronic effects of combined mTOR inhibition and ionizing radiation, and established effective CCI-779 concentrations in several human glioma cell lines. Phosphorylation of RPS6 was reduced by CCI-779 alone in a concentration-dependent manner in all cell lines with no apparent differences between PTEN wild-type and PTEN-mutant cell lines (Supplementary Figure S1a ). Ionizing radiation did not modulate the extent of RPS6 dephosphorylation induced by CCI-779 in LN-308 cells (Supplementary Figure S1b) .
CCI-779 alone induced a G1 cell cycle arrest in LN-308 glioma cells while irradiation induced a G2/M arrest. CCI-779 further enhanced the G2/M cell cycle arrest caused by irradiation (Figure 1d ). Consequently, CCI-779 increased the anti-clonogenic effects of irradiation ( Figure 1e ) and synergistically impaired the sphere-forming capacity of glioma-initiating cells (GICs) in the combined treatment (Figure 1f) . Similarly, induction of autophagy was stronger in the combination of CCI-779 and irradiation (Supplementary Figure S1c ), yet without a significant effect on apoptosis (Supplementary Figure S1d) . In summary, the combination of CCI-779 and irradiation exerts promising cytostatic antiglioma effects. We validated by quantitative reverse-transcription PCR (qRT-PCR) downregulation of RGS4 in LN-308 glioma cells in response to CCI-779, irrespective of irradiation (Figure 3a) . Notably, in PTENmutant glioma cells, a CCI-779 concentration of 10 nmol/l was sufficient to abrogate RGS4 expression, whereas in PTEN wild-type cells, 0.5-10 mmol/l was necessary to achieve an equipotent effect, suggesting that the protective effect of a PTEN wild-type status can be overcome in a concentration-dependent manner (Figure 3b) . Moreover, downregulation of RGS4 was specific to mTOR inhibition and not achievable through common cytostatic compounds such as doxorubicin (Supplementary Figure S4) . Specific silencing of RGS4 in LN-308 cells resulted in an 80% decrease in invasion, and thus mimicked the anti-invasive effect of CCI-779 even to a more pronounced extent ( Figure 3c and Supplementary Figure S5) . Conversely, stable overexpression of RGS4 led to a 62% augmentation in invasion (Figure 3c ). Importantly, RGS4 overexpression in LN-308 cells counteracted the effect of CCI-779 on invasiveness, proving that the anti-invasive effects of CCI-779 treatment were essentially mediated through RGS4 signaling ( Figure 3d ).
We then asked whether RGS4 exhibits proinvasive properties in vivo, too. To this end, we used human LN-308 glioma cells constitutively overexpressing RGS4 (Figures 3e and f) . T2-weighted cranial MRI, appropriate to display invasive growth patterns, on day 48 demonstrated a five-fold increased mean lesion volume of RGS4 overexpressing compared with control-transfected gliomas ( Figure 3g ). Histologically, RGS4-overexpressing gliomas displayed invasive growth and marked satellite formation compared with bulky control tumors ( Figure 3h ).
The feedback activation of AKT is abolished by a dose-dependent inhibition of mTORC2 Rapalog-based inhibition of mTOR activates AKT by phosphorylation while suppressing mTORC1 signaling, 23 and AKT activation during mTOR inhibition is tightly associated with the development , two known pharmacodynamic biomarkers for intact mTORC2 signaling. 24, 25 This was paralleled by an 
Abbreviations: IHC, immunohistochemistry; PTEN, phosphatase and tensin homolog deleted on chromosome 10; GIC, glioma-initiating cell; IC50, half maximal inhibitory concentration 50%; M, methylated; mut, mutated; SMA, spontaneous murine astrocytoma; U, unmethylated; WB, western blot; wt, wild-type. All glioma cells were analyzed for PTEN cDNA sequence, PTEN promoter methylation, PTEN protein expression, and phosphorylation of AKT at T308 and S473. Paraffin-embedded tumor specimens parental of the GIC cultures were assessed by PTEN-specific IHC. In-frame point mutation R55S plus d56/70 (corresponds to an in-frame deletion of exon 3).
f In-frame point mutation M134I. RGS4 suppression optimizes glioma treatment M Weiler et al increase in phosphorylation of AKT S473 . However, at 10 mmol/l, CCl-779 also disrupted mTORC2 activity and reduced AKT S473 phosphorylation, suggesting that feedback activation of AKT during mTORC1 inhibition at low concentrations was mediated by mTORC2 kinase activity and can be overcome, at least in part, by high-dosed CCI-779 (Figure 4a ).
CCI-779-mediated suppression of invasiveness is regulated through both mTORC1 and mTORC2 Next, we examined whether regulation of RGS4 was mediated through signaling of mTORC1, mTORC2, or both. We approached this issue using siRNA-mediated knockdown transfectants of LN-308 cells targeting the mRNAs of two interacting proteins, mTOR specifically assembles with, to form either mTORC1 or mTORC2: Raptor and Rictor, respectively. Silencing either Raptor or Rictor resulted in downregulation of RGS4 mRNA and protein (Figure 4b and c) . Moreover, both knockdown transfectants were less invasive than control transfectants to an extent that significantly exceeded the cytostatic effect of suppressing mTOR activity (Figure 4d and e) .
Recently published work suggested inhibition of RGS4 expression by the PI3K/AKT/glycogen synthase kinase (GSK)-3b pathway. 26 As GSK-3b is inactivated by phosphorylation through AKT kinase activity, we asked whether RGS4 could be regulated through AKT upon its feedback activation at low CCI-779 concentrations (Figure 4a ). We found CCI-779 at 10 nmol/l abolished RGS4 expression, but did not alter the phosphorylation of GSK-3b at S 9 (Supplementary Figure S6a) . Conversely, dephosphorylation-mediated activation of GSK-3b promoted by the protein kinase C-b inhibitor enzastaurin was not accompanied by an increase in mRNA or protein expression of RGS4 (Supplementary Figure S6b) . In summary, RGS4-dependent glioma-cell invasiveness is controlled through both mTOR complexes, mTORC1 and mTORC2, and regulated largely independent from AKT. mTOR inhibition reduces RGS4 expression in vivo Finally, we tested whether the suppression of invasion-associated RGS4 by mTOR inhibition is of relevance in vivo (see Figure 1b) . Expression of RGS4 was almost abolished in all CCI-779-treated tumors regardless of irradiation (Figure 5a ). We also verified by immunoblot that RGS4 was suppressed in these cells in response to CCI-779 (Figure 5b ). In addition to considerable control of tumor growth, the combined treatment regimen of CCI-779 and RT also reduced the expression of invasion-driving RGS4, even in a highly tumorigenic, supposedly less-responsive PTEN wild-type tumor.
CCI-779 in combination with RT or lomustine Among 12 individual treatments of patients with highly recurrent glioblastomas at the University Medical Center in Heidelberg, Germany, CCI-779 in combination with RT (n ¼ 7) or lomustine (n ¼ 5) resulted in objective tumor responses in three patients of the RT group and a median progression-free survival interval of 4.8 months (Table 2) .
DISCUSSION
Here we report and molecularly define that combined administration of ionizing radiation together with mTOR inhibition controls invasiveness in an invasion-prone cancer type, glioblastoma. Given the strong cytostatic and anti-invasive effects of CCI-779 as demonstrated in our study, why have mTORantagonizing regimens, whether applied as single-agent therapy or combined with EGFR inhibition, produced disappointing results in clinical trials for recurrent glioblastoma? First, it is conceivable that mTOR-antagonizing strategies are insufficient when applied as monotherapies, but beneficial when administered in combination with a cytostatic or cytotoxic regimen, for example, radiation therapy or lomustine (Table 1) , and too toxic if applied in combination with radiation and chemotherapy. 27 A second explanation could be the switch from a proneural to a mesenchymal phenotype, 28 preventing anti-tumor effects of PI3K/AKT/mTOR targeting. A third reason proposed recently could be that mTOR-antagonized glioma cells develop protection from hypoxia-induced cell death and might thus better tolerate the adverse conditions of the hypoxic microenvironment within unresectable tumor burdens frequently faced at recurrence. 29 Hence, macroscopically complete tumor resection minimizing the occurrence of hypoxia could be a favorable predictive factor for the responsiveness towards mTOR inhibition. Fourth, dosing might be critical to prevent unwanted AKT activation.
We demonstrate here that mTOR inhibition may not only be an attractive combination for RT, but also suppresses an unwanted effect of RT, that is, glioma cell migration and invasion, mediated in part by downregulation of RGS4, a newly identified potent driver molecule of glioma-cell invasiveness (Figure 3) . RGS4 belongs to the superfamily of RGS proteins that comprises, in mammalian cells, more than 30 molecules that are important regulatory components of signal transduction pathways initiated through heterotrimeric guanine nucleotide-binding proteincoupled receptors. 30 RGS proteins are linked to the initiation and progression of cancer. 31 They serve as regulatory molecules that act as GTPase-activating proteins, and thus shorten the duration and reduce the magnitude of heterotrimeric guanine nucleotide-binding protein-coupled receptors signaling that underlies a wide variety of cellular processes, including cell motility. 32, 33 RGS4 has a role in controlling cancer-cell invasiveness. In breast cancer cells, RGS4 suppresses cell migration and invasion by disrupting Ras-related C3 botulinum toxin substrate 1-dependent lamellipodia formation, and downregulation of RGS4 by proteasome degradation resulted in a metastatic phenotype. 34 In contrast, in glioma cells, a screen for genes overactivated in highly migratory clones led to the identification of RGS3 and RGS4, and both molecules were demonstrated to mediate enhanced adhesion and chemotaxis of U373MG glioma cells upon overexpression in vitro. 35 However, this method seems limited in that overexpression of a protein can change the stoichiometry of signaling molecules and may not always reflect endogenous specificity. We find that the level of RGS4 expression in glioma cells correlates with the extent of invasiveness (Figure 3) , that is, gene silencing of RGS4 reduces invasion, whereas overexpression has the opposite effect. Notably, CCI-779 not only suppresses RGS4-induced invasiveness in vitro, but also reduces RGS4 expression in an intracerebral mouse model ( Figure 5 ) and can thus be targeted by a clinically approved agent. With respect to the above-mentioned effects in breast carcinoma cells, 34 it seems likely that RGS4 functions in cancer cells are tumor type-specific and should hence be examined thoroughly before therapeutic targeting is considered. RGS4 is enriched and widely expressed in the mammalian brain, 36 making it particularly relevant for brain tumor research. Furthermore, changes in RGS4 expression or activity have been linked to other major central nervous system disorders, including Parkinson's disease, schizophrenia and drug addiction. [37] [38] [39] Therefore, RGS4 has been increasingly recognized as a promising therapeutic target for inhibition, and specific drug development is currently under way. 40 Our findings showing that CCI-779 elicits anti-proliferative and anti-invasive effects in combination with RT, leading to a reduction of adverse evasive resistance, stimulated our interest in underlying regulatory mechanisms. Recently, mTORC2 has been recognized as an emerging factor in cancer and a promising candidate target for inhibition. Consequently, a number of RGS4 suppression optimizes glioma treatment M Weiler et al (FKBP12-independent) ATP-competitive mTOR kinase inhibitors, for example, Torin1, PP242, PP30, have been developed that target both mTOR complexes at similarly low IC 50 values, and considerations to develop mTORC2-specific inhibitors are currently under way. 41 In contrast to rapamycin and its analogs that have a well-established safety profile, it remains to be evaluated whether this new class of ATP-competitive mTOR inhibitors will have an impact in the clinic. Meanwhile, our data implicate that, in glioblastoma and potentially also in other neoplastic cells, mTORC2 is targetable by the rapalog inhibitor CCI-779 at clinically relevant concentrations: In PTEN-mutated glioma cells, CCI-779 applied within the nanomolar range largely suppressed mTORC1 activity, resulting in decreased expression of RGS4 (Figures 3a and b) , paralleled by impaired invasiveness ( Figures  3d, g and h, and Figure 5a ). As a consequence, a feedback loop through mTORC2 signaling activates AKT by phosphorylation at RGS4 suppression optimizes glioma treatment M Weiler et al the critical regulatory site S 473 required for maximal AKT kinase activity, leading to unwanted effects such as increased cell survival and invasiveness (Figure 4a ). When applied in the micromolar range, CCI-779 overcomes the protective effect of a PTEN wildtype status, inhibits both mTOR complexes at a time, and thus prevents the induction of resistance through feedback activation of AKT by mTORC2 (Figure 3b and Figure 4a ). Previous evidence as to the role of PTEN as a predictor of responsiveness to mTOR inhibition in glioblastoma 9, 10, 42, 43 have been conflicting. Our data suggest that PTEN is only of limited value in predicting the sensitivity of glioma cells to CCI-779 (Table 1 and Supplementary Figure S2 ). For instance, the sensitivity of the two PTEN wild-type cell lines LN-428 and LN-18 resembled that of PTEN mutant cells (Supplementary Figure S1a) . In addition, the concerted inhibition of both mTOR complexes results in a more efficacious suppression of RGS4, leading to a tighter control of glioma-cell invasiveness (Figure 3b and Figure 4a ). In line with recent propositions favoring a dual or even sole inhibition of mTORC2, 41 we conclude that combined inhibition of mTORC1 and mTORC2 is beneficial, and can realistically be attained, at least in glioma, as the peak concentration of CCI-779, following an intravenous infusion of just 25 mg that reaches 500 nmol/l and through levels of 75 mg, the dose registered for mantle cell lymphoma, that are 4500 nmol/l.
Taken together, CCI-779 optimizes the efficacy of RT by enhancing cytostatic effects and holding the proinvasive consequences of this central therapeutic modality in check. In this regard, inhibition of mTOR with CCI-779 for the treatment of glioblastoma may be most successful in the setting of first-line treatment, when macroscopically complete resections are more likely feasible than at relapse, and radiation therapy is subsequently administered. Hence, a current controlled phase II trial on CCI-779 in combination with RT, but no temozolomide as first-line treatment of glioblastoma will assess whether these results translate into a clinically favorable outcome (EudraCT number 2008-003003-31).
MATERIALS AND METHODS

Cell culture, reagents and transfections
The human malignant glioma cell lines LN-308, LN-229, LN-428 and LN-18 were provided by N de Tribolet (Lausanne, Switzerland). Importantly, our LN-229 cells still harbor the wild-type TP53 gene and were therefore renamed LNT-229 (T for Tuebingen) for clarification. U87MG and T98G glioma cells were purchased from the American Type Culture Collection (Manassas, VA, USA). The murine glioma cell line SMA-560 was provided by DD Bigner (Durham, NC, USA). Glioma cells were maintained at standard conditions. GIC cultures T269 and T325 were grown as previously described 44 using minor modifications. 45 CCI-779 (Wyeth Pharma GmbH, Muenster, Germany), doxorubicin (Sigma-Aldrich, Taufkirchen, Germany) and the PKC-b inhibitor enzastaurin (LY317615), purchased from Selleck Chemicals LLC (Houston, TX, USA), were dissolved in dimethyl sulfoxide. Cells were irradiated in a GE Healthcare Buchler (Braunschweig, Germany) radiation device OB58 using a cesium-137 source.
ON-TARGET-plus SMART-pool siRNA by Dharmacon RNA Technologies (Lafayette, CO, USA) was used to knock down RGS4 (NM_005613; Smartpool No. L-009900), Rictor (NM_152756; Smartpool No. L-016984) and Raptor (NM_020761; Smartpool No. L-004107). ON-TARGET-plus siControl Nontargeting Pool (D-001810-10-05, Dharmacon) and transfections without siRNA were used as negative controls. Stable overexpression of RGS4 in LN-308 glioma cells was achieved by transfecting the pCR3.0 eukaryotic expression vector (Invitrogen, Karlsruhe, Germany) harboring human RGS4 cDNA (pCR3.0-RGS4; a gift from T Wieland, University of Heidelberg, Mannheim, Germany) using the Fugene HD Transfection Reagent (Roche Diagnostics, Mannheim, Germany) and selection with G418 (Sigma-Aldrich). pCR3.0 served as an empty vector control.
Microarray analysis
For gene expression analyses, LN-308 glioma cells treated with CCI-779 at 10 nmol/l or dimethyl sulfoxide as a vehicle control for 48 h were irradiated at 4 Gy or not, and exposed, for another 48 h, to continued treatment with CCI-779 and dimethyl sulfoxide, respectively. Total RNA was extracted using the RNeasy Kit (Qiagen, Hilden, Germany). RNA integrity was assessed with a 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Only samples with an RNA integrity number above 7 were used for further processing. Sample labeling with the Low RNA Input Linear Amplification Kit and hybridization on 4 Â 44K Whole Human Genome Microarrays (Agilent) were performed according to the manufacturer's protocol. In brief, 1 mg of total RNA was subjected to reverse transcription and subsequent cRNA synthesis, and labeling with Cy3-or Cy5-CTP. Samples were hybridized against universal human reference RNA (Agilent), dye swap experiments were included. Data processing was performed using ChipYard (http://www.dkfz.de/genetics/ChipYard), an in-house developed R-based platform. Normalized data were further analyzed using the open source platform Chipster (http://chipster.sourceforge.net/). Differentially expressed genes were identified using the implemented empirical Bayes method, 46 with adjustment for multiple testing according to Benjamini-Hochberg and a significance threshold of Po0.05. The microarray data have been deposited in NCBI's Gene Expression Omnibus 47 under accession number GSE24232 (http://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GSE24232).
Quantitative reverse-transcription PCR qRT-PCR was done as described. 48 RGS4 expression results were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Expression of Raptor and Rictor was normalized to the eukaryotic translation elongation factor 1 (eEF1). Primer sequences are given in Supplementary Table S1 .
Immunoblot
Preparation of cell lysates and immunoblots were performed as described. 49 Antibodies are given in Supplementary Table S2 . 
Flow cytometry
All flow cytometry work was carried out on a BD FACSCanto II flow cytometer (BD Biosciences, Heidelberg, Germany), and results were analyzed using FACSDiva 6.1 software (BD Biosciences). The BrdU-FITC antibody is given in Supplementary Table S2 . Autophagy was assessed using acridine orange (Polyscience, Warrington, PA, USA) staining in phenol red-lacking Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and flow cytometric measurement of the green and red fluorescence emission of 10 4 cells. Percentage of five was set as the autophagic baseline level in vehicle-treated control cells. Apoptosis was measured by annexin V-FITC (Biocat, Heidelberg, Germany) staining according to standard procedures and flow cytometric analysis at 488 nm.
Assessment of PTEN status
Sequence analysis of PTEN-specific cDNAs was done in comparison with the respective database entries for human or murine PTEN mRNAs.
Sequence primers are listed in Supplementary Table S1 . Immunoblot analysis of PTEN levels and AKT phosphorylation at T 308 and S 473 was carried out as described. 49 PTEN-specific immunohistochemistry was performed on 3-mm sections from paraffin-embedded patient tumor tissue, with endothelial cells as an internal positive control for PTEN positivity. Antibodies are listed in Supplementary Table S2 . Methylationspecific PCR was used to analyze the PTEN promoter region for potential methylation-mediated epigenetic silencing, using 1 mg of genomic DNA treated with sodium bisulfite using the Qiagen EpiTect Kit (Qiagen). Primers are listed in Supplementary Table S1 .
Clonogenicity and GIC sphere-formation assays Clonogenic capacity was assessed by seeding 100 glioma cells suspended in culture media and counting of macroscopically visible colonies at 96 h. Sphere-formation capacity of GICs was determined by seeding dissociated cells derived from sphere-forming GIC cultures at 100 cells per well in a 96-well plate. CCI-779 or dimethyl sulfoxide were added as indicated and refreshed every 48 h, as well as the GIC growth factors basic fibroblast growth factor and EGF (20 ng/ml each). In some experiments, GICs were irradiated at 8 Gy, 24 h after seeding. Number and size of microscopically visible spheres were determined after 14 days in culture.
Cell viability assays
Glioma cells were stained with trypan blue (Invitrogen) and counted automatically using a Vi-Cell XR cell viability analyzer (Beckman Coulter, Krefeld, Germany). Crystal violet stainings were performed as described. 49 In vitro invasion assays Invasion of glioma cells in vitro after indicated pretreatments was assessed in Boyden chamber assays (BD Biosciences). To disentangle invasion-from proliferation-specific effects, all invasion data presented were normalized to cell viability as assessed by crystal violet stainings run in parallel at identical experimental conditions. Multicellular glioma spheroids of glioma cell lines were obtained and evaluated as described. 49 Comparative real-time analysis of cell proliferation and invasion Cell proliferation and invasion were independently monitored using the xCELLigence Real-Time Cell Analyzer system (RTCA; Roche Diagnostics) allowing real-time, label-free cellular analysis. Following indicated pretreatments, glioma cells were harvested and seeded in quadruplets at a RGS4 suppression optimizes glioma treatment M Weiler et al total of 4 Â 10 4 suspended cells to each chamber of the RTCA system. Proliferation and invasion were simultaneously monitored in separate plates of the RTCA system for 24 h, and growth curves were analyzed using the RTCA software 1.2. The dimensionless cell index, derived as a relative change in measured electrical impedance caused by proliferated or invaded cells, reflects the proliferation and invasion behavior of monitored cells, respectively. To disentangle invasion-from proliferation-specific effects, the cell index for invasion was normalized to the cell index for proliferation at each monitored time point.
Animal experiments and histology
All animal work was approved by the governmental authorities (Karlsruhe, Germany) and in accordance with the NIH 'Guide for the Care and Use of Laboratory Animals'. Glioma cells were stereotactically implanted into the right brain hemisphere of CD1 nu/nu mice (Charles River Laboratories, Sulzfeld, Germany) or VM/Dk mice (in-house breeding facility, DKFZ, Heidelberg, Germany) at a depth of 3 mm. A detailed description of all animal work and histology is given in the Supplementary Materials and Methods.
Clinical case series
The German law allows individual treatments of patients in an otherwise desperate medical situation. The 12 patient cases summarized were treated on an individual basis according to high institutional standards at the University Medical Center in Heidelberg, Germany, for example, weekly clinical assessment and 6-weekly MRI, but not within a clinical trial protocol. In seven patients, weekly CCI-779 at 25 mg per week flat dose was combined with re-irradiation at 18 Â 2 Gy for 3 weeks and 3 days, starting 1 week after the first dose of CCI-779. The other five patients were treated with lomustine at 130 mg/m 2 once every 6 weeks, starting together with CCI-779. Tumor response was assessed according to the Response Assessment in Neuro-Oncology Working Group criteria. 50 Progression-free survival was determined from the first treatment with CCI-779 until clinical or radiographic tumor progression, depending on what occurred first.
Statistical analysis
Quantitative in vitro data are expressed as mean ± s.d., as indicated. All in vitro experiments reported here represent at least three independent replications performed in triplicate. Statistical significance was assessed by two-sided Student's t-test (Excel, Microsoft, Seattle, WA, USA). Values of Po0.05 were considered significant and asterisked. Survival data were plotted by the Kaplan-Meier method and analyzed by the log-rank test. A two-sided Fisher-Yates test was applied to correlate the PTEN status and AKT activation status with the IC 50 of CCI-779 in different glioma cell lines and GICs.
